Evidence map›Paper›PMID 38076426›Full record

ArticleFrontiers in bioengineering and biotechnology2023

M Karimi, E Sadeghi, M Zahedifar, M Nejati, H Mirzaei, Michael R Hamblin

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

M KarimiInstitute of Nanoscience and Nanotechnology, University of Kashan, Kashan, Iran.
E SadeghiInstitute of Nanoscience and Nanotechnology, University of Kashan, Kashan, Iran.
M ZahedifarInstitute of Nanoscience and Nanotechnology, University of Kashan, Kashan, Iran.
M NejatiAnatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, Iran.
H MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
Michael R HamblinDepartment of Dermatology, Harvard Medical School, Boston, MA, United States.
University of Kashan · IRKashan University of Medical Sciences · IRHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MgO nanoparticles (NPs) and carbon dots (C-dots) were synthesized by co-precipitation and hydrothermal techniques. In the next step, as-synthesized NPs were modified by C-dots. Then, polyethylene glycol (PEG) was conjugated with MgO/Cdots. Finally, Doxorubicin (Dox) as an anticancer drug was loaded on MgO/Cdots/PEG nanocomposites. The XRD pattern showed the characteristic peaks of C-dots and MgO. The FTIR spectrum showed that MgO/C-dots possessed the carboxyl functional groups, allowing DOX to be loaded onto MgO/C-dots/PEG through hydrogen bonds. The particle size of MgO, C-dots, MgO/C-dots, and MgO/C-dots/PEG/DOX was 20-30, 5-10, 30-40, and 100-130 nm, respectively, using TEM, DLS, and FESEM techniques. MgO, MgO/C-dots, and MgO/C-dots/DOX were fluorescent NPs when excited by a UV source. Anthracene and methylene blue were used as fluorescent probes to identify the reactive oxygen species (ROS) produced by UV excitation. The activity of MgO/C-dots and MgO/C-dots/DOX against colorectal cancer (C26) cells, after repeated 5-min illumination with both UV-light and red light LEDs, were measured by MTT assay. C26 cancer cells incubated with DOX-loaded MgO/C-dots and exposed to either wavelength (UV and red) killed ∼70% of cells. The green synthesized nanocomposites could act as anti-cancer photosensitizers probably by a photocatalytic mechanism.

Indexed as

anti-cancerin vitroMgO nanoparticlesphotodynamic therapyphototoxicity

Identifiers

PMID38076426
PMCPMC10698745
OpenAlexW4388912592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.